Background: Biotin-responsive basal ganglia disease (BBGD) is an autosomal recessive neurometabolic disorder. It is characterized by sub acute encephalopathy with confusion, seizure, dysarthria and dystonia following a history of febrile illness. If left untreated with biotin, the disease can progress to severe quadriparesis and even death. Method: A retrospective chart review of 18 patients with BBGD from two tertiary institutions describing their clinical, magnetic resonance imaging and molecular findings was conducted.
Background
Biotin-responsive basal ganglia disease (BBGD), also known as thiamine metabolism dysfunction syndrome-2 (THMD2) (MIM: 607483), is an autosomal recessive inherited neurometabolic disorder. BBGD was first described by Ozand et al. in 10 patients, of whom 8 were Saudi, 1 was Syrian and 1 was Yemeni. The disease is characterized by sub acute encephalopathy with confusion, dysarthria and dysphagia with occasional supranuclear facial nerve palsy or external ophthalmoplegia that progresses to severe cogwheel rigidity, dystonia and quadriparesis with a vague history of febrile illness [1] . In 2005, the disease was mapped to chromosome 2q36. 3 and was found to result from a mutation in the SLC19A3 gene that encodes hTHTR2, a second thiamine-transporter [2] . Subsequently, cases have been reported in patients of different ethnicities including those of Lebanese, Portuguese, Indian and Japanese origins [3] [4] [5] [6] . Neuroradiological findings include bilateral abnormal signal intensity in the basal ganglia with swelling during acute crises [1, [3] [4] [5] [6] , specifically in the central part of the caudate heads and in part or all of the putamen [1] . Additionally, abnormal signal intensity in the thalami [6] , globi pallidi [3] , white [1] , and brain and cerebellar atrophy [6] are also observed.
BBGD responds to the administration of high doses of biotin (5-10 mg/kg/day) [1, [3] [4] [5] [6] , and the symptoms reappear within 1 month if biotin is discontinued [1] . Although the probands did not respond to thiamine, carnitine, phenobarbital or diazepam treatment in the original report [1] , the patients showed improvement with the addition of thiamine to the biotin therapy in another reports [5, 6] .
Thus far, only 20 cases of BBGD have been described worldwide, and there are anecdotal reports in the literature regarding the natural history of the disease, its neurological outcomes and the genotype-phenotype correlation [1, [3] [4] [5] [6] .
In this study, we report the natural history, genotypephenotype correlation, biochemical and molecular findings, features on Magnetic Resonance Imaging (MRI) and the importance of thiamine in the treatment regimen of this disease. This large cohort of patients affected with this disease and their results should contribute to the understanding of the natural history and treatment of this devastating neurometabolic disease.
Method
A retrospective chart review of BBGD patients attending the Biochemical Genetics (Metabolic) and Neurology clinics between 2003 and 2012 was conducted. All BBGD patients from King Abdulaziz Medical City (KAMC) and King Khalid University Hospital (KKUH), Riyadh, Saudi Arabia, were included in the study. The diagnosis of BBGD was confirmed in all living participants and in one deceased individual based on DNA molecular testing. This study was approved by the ethics review boards of all participating institutions.
Result
In total, 18 patients were included (15 from KAMC and 3 from KKUH). Table 1 , Table 2 and Table 3 summarize the demographic information and the results of clinical, molecular and treatment regimens for all patients. All patients were Saudi and the male to female ratio was 1:1. The oldest patient was 23 years old with moderate motor and speech deficits, while the youngest was 15 months old with normal development.
Clinical history and examination
Consanguinity was confirmed in 17 of the 18 (95%) patients. Eight patients were from three families (see Table 1 ), and 9 of the 18 (50%) patients had a positive family history of a similarly affected sibling. Thirteen of the 18 (72%) patients came from the same tribe.
The age of onset is variable, but onset commonly occurs between 3 and 4 years (45%). All patients presented with the classical clinical features of subacute encephalopathy (confusion, drowsy, altered level of consciousness) and ataxia triggered by febrile illness. Seizures occurred in 13 of the 18 (72%) patients, and the seizures were mainly partial or generalized tonic-clonic seizures. Neurological examination showed: extrapyramidal sign dystonia and/or dysarthria were found in 12 of the 18 (67%) patients. quadriparesis and hyperreflexia in 9 of 18 (50%). Fundus examination were normal in all patients.
Investigations
All of the following were unremarkable which includes: lactate level in blood and CSF, ammonia, biotinidase, creatine phosphokinase, acylcarnitine profile, copper, ceruloplasmin, blood for biotin and thiamine level, plasma aminoa acids, urine for amino acids, urine for organic acids, liver enzymes, coagulation profile, lipid profile and cerebrospinal fluid for cell counts, protein, glucose and culture. Magnetic resonance imaging findings (see Figure 1 ) consisted of abnormal signal intensity at the caudate and putamen with diffuse involvement of the brain including the cortical and subcortical white matter and the infratentorial region, while atrophy and necrosis of the basal ganglia was demonstrated in all patients who had MRIs during chronic follow-up. Cerebellar, thalami and brain stem involvement were confirmed in 4 of the 13 (31%) patients, while one patient had a spinal lesion with increased T2 signal intensity, particularly in the cervical region. Fifteen of the 18 (83%) patients were diagnosed based on DNA molecular testing, and all were found to have the same homozygous missense mutation in exon 5 of the SLC19A3 gene ( Table 2) ; their parents were heterozygous for this mutation. The remaining three patients were diagnosed retrospectively after the diagnosis of their younger siblings.
Follow up and outcome
In 8 of the 18 (45%) patients, the diagnosis was delayed, while immediate diagnosis was achieved in 7 individuals. Four of the 18 (22%) patients died. Three patients died because treatment was not initiated due to lack of diagnosis. One patient who was diagnosed died at 26 years of age following an acute crisis; he had been receiving biotin therapy for 18 years. One-third of the patients showed mild to moderate neurological deficit, mainly in speech and motor function; one-third of the patients were normal; and two patients had severe global neurological deficits and spastic quadriplegia. In general, the cognitive outcome is better than speech and motor outcomes. All diagnosed patients improved with biotin (5-10 mg/kg/day) therapy while alive. The maximum dose of biotin was used 12 mg/kg/day, the dose schedule range from 1-3 times daily with no consistent regimen and the tablet strength was 10mg tablet. Six of the 18 (33%) patients had a recurrence of acute crises while on biotin alone, but after the addition of thiamine, there were no recurrences of those crises.
Discussion
In this study, we report the largest cohort to date of patients with BBGD. Our results support the findings of previous reports regarding the classical clinical presentation, the high prevalence of this disease in Saudi Arabia compared to other countries, the deterioration and death of patients who do not receive biotin treatment, autosomal recessive inheritance, the importance of biotin in treatment regimens and the cause of the disease in a mutation of the SLC19A3 gene, which was found in all patients [1, [3] [4] [5] [6] . Our study demonstrated the following important points:
The natural history and the dosage regimens for biotin and/or thiamine in BBGD patients are incompletely understood Previous reports showed highly variable neurological outcomes even among siblings from the same family [1, [3] [4] [5] [6] . Ozand et al. reported that 5 of 10 (50%) patients with BBGD were normal with 5-10 mg/kg/day of biotin over a variable period of follow-up ranging from 5 to 10 years [1] , while 5 mg/kg/day of biotin was ineffective in another report, and the patient was bedridden [6] . Interestingly, one BBGD child responded well to lower dosages of biotin (5-30 mg/day) [3] . Furthermore, Debs et al. reported on two siblings with BBGD, a 33 year old and a 29 year old, both had the same mutation. The man responded well to biotin alone, while the woman did not improve until thiamine was added to the treatment regimen. This significant heterogeneity demonstrates the complexity and ambiguity of the natural history and treatment of BBGD. Furthermore, this cohort demonstrated intrafamilial heterogeneity as we observe different outcomes within siblings of the same family, same environments and same molecular findings (see Table 1 ). However, the favorable outcome could be related to early initiation of treatment in several of them.
Thiamine and biotin are essential in the treatment regimens of BBGD In original reports, thiamine was not effective [1] . However, one-third of the patients reported in this cohort showed recurrence of acute crises while on biotin alone, but with the addition of thiamine, the recurrence of these crises was prevented. This result supports the hypothesis that the impairment of thiamine transport in the brain has a critical role in this disorder. Furthermore, the SLC19A3 gene encodes hTHTR2, a second thiamine-transporter and not a biotin transporter [2] . In fact, hTHTR2 demonstrates 48% structural identity to hTHTR1, which is also a thiamine transporter, while demonstrating only 17% identity with hSMVT, which is a known biotin transporter [7] . Additionally, Subramanian et al. proved that biotin is not a substrate for hTHTR2 [7] . This evidence supports the importance of thiamine in the treatment of this disease but leaves the mechanism by which BBGD patients improved dramatically on biotin, as we observed in 100% of our cohort, unclear. However, it could be hypothesized that the biotin and thiamine transporters in the basal ganglia are closely associated and thus act synergistically [7] . Therefore, we recommend that the treatment regimen for patients with BBGD contain both thiamine and biotin.
Factors contributing to clinical outcome
The gap between the age of disease onset and the date of diagnosis correlates directly with the neurological outcome. Eight of the 18 patients who had a delayed diagnosis displayed mild to moderate neurological deficits, while seven patients who were diagnosed immediately achieved normal development. Another important factor is the number of attacks of acute crises, as a poor outcome is directly associated with more acute crises in the present patients. All those children with normal outcome had only one event. Additionally, the immediate treatment with biotin and thiamine is an important aspect that contributes to normal outcomes, as reported cohort showed no recurrence of crises on this regimen for a period of up to 5 years of follow-up. However, it is very difficult to extrapolate firm conclusion with regards to aforementioned factors as the median follow up of normal children were 16 months (1 month-3 year) which is too short compare to poorer outcome individuals.
Magnetic resonance imaging commonly shows an effect in the basal ganglia and could involve other parts of the brain and spinal cord
In the original report by Ozand et al., the MRI findings consist of bilateral necrosis in the basal ganglia, particularly at the central part of the caudate heads and part or all of the putamen with severe edema during the acute crisis in addition to white matter involvement at the greywhite matter junction [1] . Subsequent reports confirmed these findings and added the involvement of the globi pallidi, thalami, cerebellum and brain stem [3, 6] . Our largest cohort demonstrated these findings and showed abnormal signal intensity and swelling at the caudate and pautamen with diffuse involvement of the brain including the cortical, subcortical white matter and infratentorial region, while atrophy and necrosis of the basal ganglia appeared during chronic follow-up. Cerebellar, thalami and brain stem involvement are found in one-third of patients (see Figure 1 ). Interestingly, one patient demonstrated spinal cord involvement with increased T 2 signal intensity particularly at the cervical region, which was not reported previously. This could be easily explained by the fact that previous patients did not undergo MRI of the spine, and neither did the patients in this report. It would be valuable to perform spinal MRI for all patients affected with this disease to see the extent of this finding.
The genotype-phenotype correlation is poor and an intron mutation (c.980-14 A>G), which was discovered in 2 siblings in a heterozygous state of European ancestry. Despite having the same mutation, children from the same family have extremely variable outcomes, ranging from normal to severely handicapped [1] [2] [3] 5, 6] .
Future directions
Despite its discovery 14 years ago, several questions regarding BBGD remain unanswered. Animal models are vital to understanding the pathophysiology of thiamine and biotin transport in the brain, particularly the levels of biotin and thiamine in the brain at the basal ganglia. This information is critical to understanding the clinical picture, complications and management of this disease. Moreover, investigators should make an effort to find a biomarker for this disease, which will help to accurately determine the appropriate dosages of biotin and thiamine to consequently improve the outcome of the disease. Finally, diagnosing more asymptomatic cases through the screening of high risk tribes and international registries to accommodate more cases of the SLC19A3 gene defect will lead to a better understanding of the natural history of the disease and will facilitate well designed treatment and outcome studies.
Conclusion
Based on the evidence obtained from our cohort, we recommend changing the name BBGD to biotin-thiamineresponsive basal ganglia disease (BTBGD). Clinicians should consider this disorder in any patients with subacute/acute encephalopathy, ataxia triggered by febrile illness and basal ganglia involvement.
